Market closed
Ironwood Pharmaceuticals/$IRWD
Ironwood Pharmaceuticals shares are trading higher after the company reported its Q1 results.
24 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Ticker
$IRWD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
253
ISIN
US46333X1081
Website
IRWD Metrics
BasicAdvanced
$115M
-
-$0.20
0.37
-
Price and volume
Market cap
$115M
Beta
0.37
52-week high
$7.19
52-week low
$0.59
Average daily volume
3.6M
Financial strength
Current ratio
3.339
Quick ratio
3.082
Long term debt to equity
-178.378
Total debt to equity
-179.337
Interest coverage (TTM)
2.16%
Management effectiveness
Return on assets (TTM)
12.03%
Return on equity (TTM)
9.73%
Valuation
Price to revenue (TTM)
0.357
Price to book
-0.34
Price to tangible book (TTM)
-0.34
Growth
Revenue change (TTM)
-23.18%
Earnings per share change (TTM)
-97.00%
3-year revenue growth (CAGR)
-9.06%
3-year earnings per share growth (CAGR)
-59.65%
What the Analysts think about IRWD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
IRWD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IRWD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
Business Wire·3 days ago
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Business Wire·2 weeks ago
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals (IRWD) has a market cap of $115M as of May 10, 2025.
What is the P/E ratio for Ironwood Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ironwood Pharmaceuticals (IRWD) stock is 0 as of May 10, 2025.
Does Ironwood Pharmaceuticals stock pay dividends?
No, Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Ironwood Pharmaceuticals dividend payment date?
Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders.
What is the beta indicator for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.